Regulation of TRPC6 ion channels in podocytes - Implications for focal segmental glomerulosclerosis and acquired forms of proteinuric diseases (Review)

Acta Physiologica Hungarica

Volumn 102, Issue 3, 2015, Pages 241-251

  Szabo T ^a   Ambrus, L ^a   Zakany N ^a   Balla, Gy ^a   Biro T ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Angiotensin II; Diabetic nephropathy; Focal segmental glomerulosclerosis (FSGS); Podocyte; Proteinuric disease; TRPC6

Indexed keywords

ANGIOTENSIN II; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; TRANSIENT RECEPTOR POTENTIAL CHANNEL C; TRPC6 PROTEIN, HUMAN;

ARTICLE; DIABETIC NEPHROPATHY; DISEASE COURSE; FOCAL GLOMERULOSCLEROSIS; GENE MUTATION; GLOMERULAR FILTRATION BARRIER; HUMAN; HYPERTENSION; PATHOGENESIS; PODOCYTE; PROTEIN PROTEIN INTERACTION; PROTEINURIA; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; ANIMAL; GENETIC PREDISPOSITION; GENETICS; GLOMERULUS FILTRATION RATE; METABOLISM; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE;

ANIMALS; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; GLOMERULAR FILTRATION RATE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; MUTATION; PHENOTYPE; PODOCYTES; PROTEINURIA; SIGNAL TRANSDUCTION; TRPC CATION CHANNELS;

EID: 84946032549     PISSN: 0231424X     EISSN: 15882683     Source Type: Journal    
DOI: 10.1556/036.102.2015.3.2     Document Type: Article

References (77)

1. Agrawal V, Marinescu V, Agarwal M, Mc Cullough PA: Cardiovascular implications of proteinuria: An indicator of chronic kidney disease. Nat. Rev. Cardiol. 6, 301-311 (2009).
2. Asanuma K, Yanagida-Asanuma E, Faul C, Tomino Y, Kim K, Mundel P: Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling. Nat. Cell Biol. 8, 485-491 (2006).
3. Benoit G, Machuca E, Nevo F, Gribouval O, Lepage D, Antignac C: Analysis of recessive CD2AP and ACTN4 mutations in steroid-resistant nephrotic syndrome. Pediatr. Nephrol. 25, 445-451 (2010).
4. Bensman A, Niaudet P: Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies. Pediatr. Nephrol. 25, 1197-1199 (2010).
5. Bousquet SM, Monet M, Boulay G: Protein kinase C-dependent phosphorylation of transient receptor potential canonical 6 (TRPC6) on serine 448 causes channel inhibition. J. Biol. Chem. 285, 40534-40543 (2010).
6. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ: Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366, 2026-2033 (2005).
7. Catalano C, Muscelli E, Quiñones Galvan A, Baldi S, Masoni A, Gibb I, Torffvit O, Seghieri G, Ferrannini E: Effect of insulin on systemic and renal handling of albumin in nondiabetic and NIDDM subjects. Diabetes 46, 868-875 (1997).
8. Chen S, He FF, Wang H, Fang Z, Shao N, Tian XJ, Liu JS, Zhu ZH, Wang YM, Wang S, Huang K, Zhang C: Calcium entry via TRPC6 mediates albumin overload-induced endoplasmic reticulum stress and apoptosis in podocytes. Cell Calcium 50, 523-529 (2011).
9. Clapham DE, Nilius B, Owsianik G (2012): Transient receptor potential channels. IUPHAR database (IUPHAR-DB). http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyld=78.
10. Clapham DE: TRP channels as cellular sensors. Nature 426, 517-524 (2003).
11. Crabtree GR: Calcium, calcineurin, and the control of transcription. J. Biol. Chem. 276, 2313-2316 (2001).
12. Damann N, Voets T, Nilius B: TRPs in our senses. Curr. Biol. 18, R880-R889 (2008).
13. Daskalakis N, Winn MP: Focal and segmental glomerulosclerosis. Cell. Mol. Life Sci. 63, 2506-2511 (2006).
14. Dietrich A, Chubanov V, Gudermann T: Renal TRPathies. J. Am. Soc. Nephrol. 21, 736-744 (2010).
15. Durvasula RV, Petermann AT, Hiromura K, Blonski M, Pippin J, Mundel P, Pichler R, Griffin S, Couser WG, Shankland SJ: Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int. 65, 30-39 (2004).
16. Durvasula RV, Shankland SJ: Activation of a local renin angiotensin system in podocytes by glucose. Am. J. Physiol. Renal. Physiol. 294, F830-F839 (2008).
17. El Hindi S, Reiser J: TRPC channel modulation in podocytes-inching toward novel treatments for glomerular disease. Pediatr. Nephrol. 26, 1057-1064 (2011).
18. Endlich N, Endlich K: Stretch, tension and adhesion - Adaptive mechanisms of the actin cytoskeleton in podocytes. Eur. J. Cell Biol. 85, 229-234 (2006).
19. Endlich N, Kress KR, Reiser J, Uttenweiler D, Kriz W, Mundel P, Endlich K: Podocytes respond to mechanical stress in vitro. J. Am. Soc. Nephrol. 12, 413-422 (2001).
20. Faul C, Asanuma K, Yanagida-Asanuma E, Kim K, Mundel P: Actin up: Regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol 17, 428-437 (2007).
21. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, Chang JM, Choi HY, Campbell KN, Kim K, Reiser J, Mundel P: The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat. Med. 14, 931-938 (2008).
22. Flannery PJ, Spurney RF: Transactivation of the epidermal growth factor receptor by angiotensin II in glomerular podocytes. Nephron Exp. Nephrol. 103, e109-e118 (2006).
23. Gloy J, Henger A, Fischer KG, Nitschke R, Mundel P, Bleich M, Schollmeyer P, Greger R, Pavenstädt H: Angiotensin II depolarizes podocytes in the intact glomerulus of the rat. J. Clin. Invest. 99, 2772-2781 (1997).
24. Greka A, Mundel P: Balancing calcium signals through TRPC5 and TRPC6 in podocytes. J. Am. Soc. Nephrol. 22, 1969-1980 (2011).
25. Gudermann T: A new TRP to kidney disease. Nat. Genet. 37, 663-664 (2005).
26. Haas M, Spargo BH, Coventry S: Increasing incidence of focal-segmental glomerulosclerosis among adult nephropathies: A 20-year renal biopsy study. Am. J. Kidney Dis. 26, 740-750 (1995).
27. Hauser PV, Pippin JW, Kaiser C, Krofft RD, Brinkkoetter PT, Hudkins KL, Kerjaschki D, Reiser J, Alpers CE, Shankland SJ: Novel siRNA delivery system to target podocytes in vivo. PLoS One 5, e9463 (2010).
28. Hildebrandt F, Heeringa SF: Specific podocin mutations determine age of onset of nephrotic syndrome all the way into adult life. Kidney Int. 75, 669-671 (2009).
29. Hinkes BG, Mucha B, Vlangos CN, Gbadegesin R, Liu J, Hasselbacher K, Hangan D, Ozaltin F, Zenker M, Hildebrandt F; Arbeitsgemeinschaft für Paediatrische Nephrologie Study Group: Nephrotic syndrome in the first year of life: Two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2). Pediatrics 119, e907-e919 (2007).
30. Hoffmann S, Podlich D, Hähnel B, Kriz W, Gretz N: Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J. Am. Soc. Nephrol. 15, 1475-1487 (2004).
31. Hofmann T, Obukhov AG, Schaefer M, Harteneck C, Gudermann T, Schultz G: Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature 397, 259-263 (1999).
32. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, Noble NA, Border W: Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 69, 105-113 (2006).
33. Hwang JH, Han SS, Huh W, Park SK, Joo DJ, Kim MS, Kim YS, Min SI, Ha J, Kim SJ, Kim S, Kim YS: Outcome of kidney allograft in patients with adulthood-onset focal segmental glomerulosclerosis: comparison with childhood-onset FSGS. Nephrol. Dial. Transplant. 27, 2559-2565 (2012).
34. Inagami T, Eguchi S, Numaguchi K, Motley ED, Tang H, Matsumoto T, Yamakawa T: Cross-talk between angiotensin II receptors and the tyrosine kinases and phosphatases. J. Am. Soc. Nephrol. 10 Suppl 11, S57-S61 (1999).
35. Jauregui A, Mintz DH, Mundel P, Fornoni A: Role of altered insulin signaling pathways in the pathogenesis of podocyte malfunction and microalbuminuria. Curr. Opin. Nephrol. Hypertens. 18, 539-545 (2009).
36. Jiang L, Ding J, Tsai H, Li L, Feng Q, Miao J, Fan Q: Over-expressing transient receptor potential cation channel 6 in podocytes induces cytoskeleton rearrangement through increases of intracellular Ca2+ and RhoA activation. Exp. Biol. Med. (Maywood) 236, 184-193 (2011).
37. Kanda S, Harita Y, Shibagaki Y, Sekine T, Igarashi T, Inoue T, Hattori S: Tyrosine phosphorylation-dependent activation of TRPC6 regulated by PLC-γ1 and nephrin: effect of mutations associated with focal segmental glomerulosclerosis. Mol. Biol. Cell 22, 1824-1835 (2011).
38. Kerti A, Csohány R, Szabó A, Arkossy O, Sallay P, Moriniére V, Vega-Warner V, Nyíro G, Lakatos O, Szabó T, Lipska BS, Schaefer F, Antignac C, Reusz G, Tulassay T, Tory K: NPHS2 p.V290M mutation in late-onset steroid-resistant nephrotic syndrome. Pediatr. Nephrol. 28, 751-757 (2013).
39. Kuipers AJ, Middelbeek J, van Leeuwen FN: Mechanoregulation of cytoskeletal dynamics by TRP channels. Eur. J. Cell Biol. 91, 834-846 (2012).
40. Kuwahara K, Wang Y, McAnally J, Richardson JA, Bassel-Duby R, Hill JA, Olson EN: TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. J. Clin. Invest. 116, 3114-3126 (2006).
41. Langham RG, Kelly DJ, Cox AJ, Thomson NM, Holthöfer H, Zaoui P, Pinel N, Cordonnier DJ, Gilbert RE: Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 45, 1572-1576 (2002).
42. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 329, 1456-1462 (1993).
43. Li SZ, McDill BW, Kovach PA, Ding L, Go WY, Ho SN, Chen F: Calcineurin-NFATc signaling pathway regulates AQP2 expression in response to calcium signals and osmotic stress. Am. J. Physiol. Cell Physiol. 292, C1606-C1616 (2007).
44. Li Z, Xu J, Xu P, Liu S, Yang Z: Wnt/β-catenin signalling pathway mediates high glucose induced cell injury through activation of TRPC6 in podocytes. Cell Prolif. 46, 76-85 (2013).
45. Mathieson PW: The podocyte as a target for therapies - new and old. Nat. Rev. Nephrol. 8, 52-56 (2011).
46. Mifsud SA, Allen TJ, Bertram JF, Hulthen UL, Kelly DJ, Cooper ME, Wilkinson-Berka JL, Gilbert RE: Podocyte foot process broadening in experimental diabetic nephropathy: Amelioration with renin-angiotensin blockade. Diabetologia 44, 878-882 (2001).
47. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N. Engl. J. Med. 310, 356-360 (1984).
48. Möller CC, Wei C, Altintas MM, Li J, Greka A, Ohse T, Pippin JW, Rastaldi MP, Wawersik S, Schiavi S, Henger A, Kretzler M, Shankland SJ, Reiser J: Induction of TRPC6 channel in acquired forms of proteinuric kidney disease. J. Am. Soc. Nephrol. 18, 29-36 (2007).
49. Mukerji N, Damodaran TV, Winn MP: TRPC6 and FSGS: The latest TRP channelopathy. Biochim. Biophys. Acta 1772, 859-868 (2007).
50. Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T, Sraer JD: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 109, 1417-1427 (2002).
51. Nijenhuis T, Sloan AJ, Hoenderop JG, Flesche J, van Goor H, Kistler AD, Bakker M, Bindels RJ, de Boer RA, Möller CC, Hamming I, Navis G, Wetzels JF, Berden JH, Reiser J, Faul C, van der Vlag J: Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. Am. J. Pathol. 179, 1719-1732 (2011).
52. Nilius B, Szallasi A: Transient receptor potential channels as drug targets: from the science of basic research to the art of medicine. Pharmacol. Rev. 66, 676-814 (2014).
53. Nitschke R, Henger A, Ricken S, Gloy J, Müller V, Greger R, Pavenstädt H: Angiotensin II increases the intracellular calcium activity in podocytes of the intact glomerulus. Kidney Int. 57, 41-49 (2000).
54. Oláh A, Szöllosi AG, Bíró T: The channel physiology of the skin. Rev. Physiol. Biochem. Pharmacol. 163, 65-131 (2012).
55. Onohara N, Nishida M, Inoue R, Kobayashi H, Sumimoto H, Sato Y, Mori Y, Nagao T, Kurose H: TRPC3 and TRPC6 are essential for angiotensin II-induced cardiac hypertrophy. EMBO J. 25, 5305-5316 (2006).
56. Ovunc B, Ashraf S, Vega-Warner V, Bockenhauer D, Elshakhs NA, Joseph M, Hildebrandt F, Gesellschaft für Pädiatrische Nephrologie (GPN) Study Group: Mutation analysis of NPHS1 in a worldwide cohort of congenital nephrotic syndrome patients. Nephron Clin. Pract. 120, c139-c146 (2012).
57. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L, Meyer TW: Podocyte loss and progressive glomerular injury in type II diabetes. J. Clin. Invest. 99, 342-348 (1997).
58. Ramsey IS, Delling M, Clapham DE: An introduction to TRP channels. Annu. Rev. Physiol. 68, 619-647 (2006).
59. Reddy GR, Kotlyarevska K, Ransom RF, Menon RK: The podocyte and diabetes mellitus: is the podocyte the key to the origins of diabetic nephropathy? Curr. Opin. Nephrol. Hypertens. 17, 32-36 (2008).
60. Reiser J, Gupta V, Kistler AD: Toward the development of podocyte-specific drugs. Kidney Int. 77, 662-668 (2010).
61. Reiser J, Polu KR, Möller CC, Kenlan P, Altintas MM, Wei C, Faul C, Herbert S, Villegas I, Avila-Casado C, McGee M, Sugimoto H, Brown D, Kalluri R, Mundel P, Smith PL, Clapham DE, Pollak MR: TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat. Genet. 37, 739-744 (2005).
62. Saleem MA: New developments in steroid-resistant nephrotic syndrome. Pediatr. Nephrol. 28, 699-709 (2013).
63. Santín S, García-Maset R, Ruíz P, Giménez I, Zamora I, Peña A, Madrid A, Camacho JA, Fraga G, Sánchez- Moreno A, Cobo MA, Bernis C, Ortiz A, de Pablos AL, Pintos G, Justa ML, Hidalgo-Barquero E, Fernández- Llama P, Ballarín J, Ars E, Torra R; FSGS Spanish Study Group: Nephrin mutations cause childhood- And adult-onset focal segmental glomerulosclerosis. Kidney Int. 76, 1268-1276 (2009).
64. Schlöndorff J, Del Camino D, Carrasquillo R, Lacey V, Pollak MR: TRPC6 mutations associated with focal segmental glomerulosclerosis cause constitutive activation of NFAT-dependent transcription. Am. J. Physiol. Cell Physiol. 296, C558-C569 (2009).
65. Somlo S, Mundel P: Getting a foothold in nephrotic syndrome. Nat. Genet. 24, 333-335 (2000).
66. Steffes MW, Schmidt D, McCrery R, Basgen JM: International Diabetic Nephropathy Study Group: Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int. 59, 2104-2113 (2001).
67. Tseng PH, Lin HP, Hu H, Wang C, Zhu MX, Chen CS: The canonical transient receptor potential 6 channel as a putative phosphatidylinositol 3, 4, 5-trisphosphate-sensitive calcium entry system. Biochemistry 43, 11701- 11708 (2004).
68. Vincenti F, Ghiggeri GM: New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. Am. J. Transplant. 5, 1179-1185 (2005).
69. Vriens J, Appendino G, Nilius B: Pharmacology of vanilloid transient receptor potential cation channels. Mol. Pharmacol. 75, 1262-1279 (2009).
70. Wang Y, Jarad G, Tripathi P, Pan M, Cunningham J, Martin DR, Liapis H, Miner JH, Chen F: Activation of NFAT signaling in podocytes causes glomerulosclerosis. J. Am. Soc. Nephrol. 21, 1657-1666 (2010).
71. Weins A, Kenlan P, Herbert S, Le TC, Villegas I, Kaplan BS, Appel GB, Pollak MR: Mutational and biological analysis of alpha-actinin-4 in focal segmental glomerulosclerosis. J. Am. Soc. Nephrol. 16, 3694-3701 (2005).
72. White KE, Bilous RW: Diabiopsies Study Group: Structural alterations to the podocyte are related to proteinuria in type 2 diabetic patients. Nephrol. Dial. Transplant. 19, 1437-1440 (2004).
73. Winn MP, Conlon PJ, Lynn KL, Farrington MK, Creazzo T, Hawkins AF, Daskalakis N, Kwan SY, Ebersviller S, Burchette JL, Pericak-Vance MA, Howell DN, Vance JM, Rosenberg PB: A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 308, 1801-1804 (2005).
74. Xu ZG, Yoo TH, Ryu DR, Cheon Park H, Ha SK, Han DS, Adler SG, Natarajan R, Kang SW: Angiotensin II receptor blocker inhibits p27Kip1 expression in glucose-stimulated podocytes and in diabetic glomeruli. Kidney Int. 67, 944-952 (2005).
75. Yoo TH, Li JJ, Kim JJ, Jung DS, Kwak SJ, Ryu DR, Choi HY, Kim JS, Kim HJ, Han SH, Lee JE, Han DS, Kang SW: Activation of the renin-angiotensin system within podocytes in diabetes. Kidney Int. 71, 1019-1027 (2007).
76. Zhang B, Shi W: Is the antiproteinuric effect of cyclosporine a independent of its immunosuppressive function in T cells? Int. J. Nephrol. 2012, 809456 (2012).
77. Zhang H, Ding J, Liu S: TRPC6 up-regulation in Ang II-induced podocyte apoptosis might result from ERK activation and NF-kappaB translocation. Exp. Biol. Med. (Maywood) 234, 1029-1036 (2009).